ES2333772T3 - Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas. - Google Patents

Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas. Download PDF

Info

Publication number
ES2333772T3
ES2333772T3 ES00989401T ES00989401T ES2333772T3 ES 2333772 T3 ES2333772 T3 ES 2333772T3 ES 00989401 T ES00989401 T ES 00989401T ES 00989401 T ES00989401 T ES 00989401T ES 2333772 T3 ES2333772 T3 ES 2333772T3
Authority
ES
Spain
Prior art keywords
polypeptide
cell
pro10272
amino acid
pro5801
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00989401T
Other languages
English (en)
Spanish (es)
Inventor
Jian Chen
Ellen Filvaroff
Sherman Fong
Audrey Goddard
Paul J. Godowski
Christopher J. Grimaldi
Austin L. Gurney
Hanzhong Li
Kenneth J. Hillan
Daniel Tumas
Menno Van Lookeren
Richard L. Vandlen
Colin K. Watanabe
P. Mickey Williams
William I. Wood
Daniel G. Yansura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/031274 external-priority patent/WO2000053752A2/en
Priority claimed from PCT/US2000/004341 external-priority patent/WO2000053756A2/en
Priority claimed from PCT/US2000/007532 external-priority patent/WO2000070050A1/en
Priority claimed from PCT/US2000/015264 external-priority patent/WO2000073452A2/en
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2333772T3 publication Critical patent/ES2333772T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
ES00989401T 1999-12-23 2000-12-20 Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas. Expired - Lifetime ES2333772T3 (es)

Applications Claiming Priority (28)

Application Number Priority Date Filing Date Title
US17209699P 1999-12-23 1999-12-23
US172096P 1999-12-23
WOUS99/31274 1999-12-30
PCT/US1999/031274 WO2000053752A2 (en) 1999-03-08 1999-12-30 Promotion or inhibition of angiogenesis and cardiovascularization
US17548100P 2000-01-11 2000-01-11
US175481P 2000-01-11
WOUS00/04341 2000-02-18
PCT/US2000/004341 WO2000053756A2 (en) 1999-03-08 2000-02-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
WOUS00/05841 2000-03-02
US19100700P 2000-03-21 2000-03-21
PCT/US2000/007532 WO2000070050A1 (en) 1999-05-14 2000-03-21 Compositions and methods for the treatment of immune related diseases
US191007P 2000-03-21
WOUS00/07532 2000-03-21
PCT/US2000/015264 WO2000073452A2 (en) 1999-06-02 2000-06-02 Compositions and methods for the treatment of immune related diseases
WOUS00/15264 2000-06-02
US21380700P 2000-06-22 2000-06-22
US213807P 2000-06-22
US64484800A 2000-08-22 2000-08-22
US644848 2000-08-22
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
WOUS00/23328 2000-08-24
US24283700P 2000-10-24 2000-10-24
US242837P 2000-10-24
PCT/US2000/030873 WO2001040465A2 (en) 1999-11-30 2000-11-10 Compositions and methods for the treatment of immune related diseases
WOUS00/30873 2000-11-10
US25364600P 2000-11-28 2000-11-28
US253646P 2000-11-28
WOUS00/32678 2000-12-01

Publications (1)

Publication Number Publication Date
ES2333772T3 true ES2333772T3 (es) 2010-03-01

Family

ID=40140243

Family Applications (7)

Application Number Title Priority Date Filing Date
ES00989401T Expired - Lifetime ES2333772T3 (es) 1999-12-23 2000-12-20 Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas.
ES07016899T Expired - Lifetime ES2379101T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos
ES10009491.1T Expired - Lifetime ES2458349T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos
ES07016901T Expired - Lifetime ES2380958T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y utilizaciones terapéuticas de los mismos
ES07016903T Expired - Lifetime ES2380812T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos
ES09009972.2T Expired - Lifetime ES2506665T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 e IL-17R y usos terapéuticos de los mismos
ES07016902T Expired - Lifetime ES2388748T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos

Family Applications After (6)

Application Number Title Priority Date Filing Date
ES07016899T Expired - Lifetime ES2379101T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos
ES10009491.1T Expired - Lifetime ES2458349T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos
ES07016901T Expired - Lifetime ES2380958T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y utilizaciones terapéuticas de los mismos
ES07016903T Expired - Lifetime ES2380812T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos
ES09009972.2T Expired - Lifetime ES2506665T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 e IL-17R y usos terapéuticos de los mismos
ES07016902T Expired - Lifetime ES2388748T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos

Country Status (10)

Country Link
EP (1) EP1240325B1 (enExample)
JP (10) JP5070117B2 (enExample)
AT (5) ATE519847T1 (enExample)
AU (1) AU2590901A (enExample)
CA (1) CA2391374A1 (enExample)
CY (1) CY1112334T1 (enExample)
DK (1) DK1240325T3 (enExample)
ES (7) ES2333772T3 (enExample)
PT (4) PT1897947E (enExample)
WO (1) WO2001046420A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
JP3577586B2 (ja) 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
WO2001064240A2 (en) * 2000-02-29 2001-09-07 Zymogenetics, Inc. Methods for promoting production of myelin by schwann cells
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
AU2001251655A1 (en) * 2000-04-18 2001-10-30 Schering Corporation Cytokine uses; compositions; methods
JP2003534013A (ja) * 2000-05-24 2003-11-18 シェーリング コーポレイション 哺乳動物レセプタータンパク質；関連試薬および方法
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1332211A2 (en) * 2000-07-26 2003-08-06 ZymoGenetics, Inc. Human cytokine receptor
EP1529843A3 (en) * 2000-08-11 2005-06-08 Eli Lilly & Company Novel secreted proteins and their uses
ES2277947T3 (es) * 2000-10-13 2007-08-01 Eli Lilly And Company Procedimientos de uso de un polipeptido afin a il-17 humana para tratar enfermedades.
US20040171109A1 (en) * 2000-11-10 2004-09-02 Dominik Haudenschild IL-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2842429A1 (en) * 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US20060281146A1 (en) * 2002-09-11 2006-12-14 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
AU2003302386B2 (en) * 2002-11-26 2010-04-01 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1599498A2 (en) * 2003-03-03 2005-11-30 Genentech, Inc. Compositions and methods for the treatment of systemic lupus erythematosis
ES2424353T3 (es) 2003-07-08 2013-10-01 Genentech, Inc. Polipéptidos heterólogos IL-17 A/F y usos terapéuticos de los mismos
WO2005051422A1 (en) 2003-11-21 2005-06-09 Celltech R & D Limited Method for the treatment of multiple sclerosis by inhibiting il-17 activity
JP2007535930A (ja) 2004-05-03 2007-12-13 シェーリング　コーポレイション 皮膚の炎症を予測するためのｉｌ−１７発現の使用；処置方法
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
EP1765865A2 (en) 2004-06-10 2007-03-28 ZymoGenetics, Inc. Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation
EP1799248B1 (en) * 2004-09-21 2009-04-08 Merck Serono SA Use of il-17f for the treatment and/or prevention of neurologic diseases
JP2009505967A (ja) * 2005-08-04 2009-02-12 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７ｂを用いた創傷の処置方法
US20070249533A1 (en) 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
JP2009526084A (ja) 2006-02-10 2009-07-16 ザイモジェネティクス， インコーポレイテッド 可溶性ＩＬ−１７ＲＣｘ４および炎症における使用法
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
JP2010509364A (ja) * 2006-11-08 2010-03-25 ザイモジェネティクス， インコーポレイテッド 創傷治癒における使用のためのｉｌ−１７ｂ
JP2010522564A (ja) 2007-03-26 2010-07-08 ザイモジェネティクス， インコーポレイテッド 可溶性ｉｌ−１７ｒａ／ｒｃ融合タンパク質および関連する方法
BRPI0908312A2 (pt) 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
WO2010103038A1 (en) 2009-03-11 2010-09-16 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
RU2537142C2 (ru) 2009-04-01 2014-12-27 Дженентек, Инк. Лечение нарушений, связанных с инсулинорезистентностью
GB0905972D0 (en) 2009-04-06 2009-05-20 Medical Res Council Antibodies against IL-17BR
BRPI1014544B8 (pt) 2009-05-05 2021-05-25 Novimmune Sa anticorpo anti-il-17f monoclonal totalmente humano isolado e composição farmacêutica compreendendo o mesmo
WO2010142551A2 (en) * 2009-06-12 2010-12-16 Ablynx N.V. Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
WO2012098113A1 (en) 2011-01-17 2012-07-26 Novo Nordisk A/S Il-21 ligands
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
SI2768859T1 (en) 2011-10-19 2018-06-29 Morphosys Ag Antagonists of il17c for the treatment of inflammatory disorders
JP6236948B2 (ja) * 2013-07-17 2017-11-29 東ソー株式会社 抗体精製用溶出液および当該溶出液を用いた抗体精製方法
KR20150050921A (ko) * 2013-11-01 2015-05-11 현대중공업 주식회사 폐열 회수용 연관식 보일러
EP3212665A2 (en) 2014-10-31 2017-09-06 F. Hoffmann-La Roche AG Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
CN107407677B (zh) 2015-01-28 2020-07-17 豪夫迈·罗氏有限公司 多发性硬化的基因表达标志和治疗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DK0817847T4 (da) * 1995-03-23 2009-10-05 Immunex Corp IL-17-receptor
EA199900869A1 (ru) * 1997-04-25 2000-12-25 Займодженетикс, Инк. Цитокин-подобный фактор 7 млекопитающих
JP2001510035A (ja) * 1997-07-16 2001-07-31 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド インターロイキン−２０
ATE442385T1 (de) * 1997-09-17 2009-09-15 Human Genome Sciences Inc Interleukin-17 rezeptor-ähnliches protein
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
WO1999032632A1 (en) * 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
ES2312205T3 (es) * 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
JP3577586B2 (ja) * 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
SI1141297T1 (sl) * 1999-01-11 2010-01-29 Schering Corp Interlevkinu-17 sorodni sesalski citokini, polinukleotidi, ki jih kodirajo uporabe
AR022237A1 (es) * 1999-01-11 2002-09-04 Schering Corp Citoquinas mamiferas purificadas; reactivos y metodos relacionados
AU2596700A (en) * 1999-03-08 2000-09-28 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU3632600A (en) * 1999-05-14 2000-12-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
EP1860188B1 (en) * 1999-07-07 2011-05-04 ZymoGenetics, Inc. Human cytokine receptor
JP2003527104A (ja) * 1999-12-23 2003-09-16 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途

Also Published As

Publication number Publication date
JP2015007091A (ja) 2015-01-15
PT1897945E (pt) 2012-03-29
PT1240325E (pt) 2010-01-07
JP2014239685A (ja) 2014-12-25
JP2008278887A (ja) 2008-11-20
ATE541931T1 (de) 2012-02-15
JP2013165712A (ja) 2013-08-29
ES2379101T3 (es) 2012-04-20
JP5070117B2 (ja) 2012-11-07
JP2012152218A (ja) 2012-08-16
ATE519847T1 (de) 2011-08-15
JP2015077137A (ja) 2015-04-23
EP1240325A2 (en) 2002-09-18
JP2009278996A (ja) 2009-12-03
HK1114638A1 (en) 2008-11-07
WO2001046420A2 (en) 2001-06-28
EP1240325B1 (en) 2009-09-30
HK1114635A1 (en) 2008-11-07
JP2010266454A (ja) 2010-11-25
WO2001046420A3 (en) 2002-05-10
ES2380958T3 (es) 2012-05-21
HK1150856A1 (en) 2012-01-13
PT1897947E (pt) 2012-03-29
DK1240325T3 (da) 2010-01-25
HK1114634A1 (en) 2008-11-07
AU2590901A (en) 2001-07-03
HK1114636A1 (en) 2008-11-07
WO2001046420A8 (en) 2002-07-04
HK1114637A1 (en) 2008-11-07
CA2391374A1 (en) 2001-06-28
JP2009159968A (ja) 2009-07-23
PT1897944E (pt) 2011-11-28
ES2506665T3 (es) 2014-10-13
ATE541930T1 (de) 2012-02-15
ATE444361T1 (de) 2009-10-15
JP5258691B2 (ja) 2013-08-07
ES2458349T3 (es) 2014-05-05
ES2388748T3 (es) 2012-10-18
ES2380812T3 (es) 2012-05-18
CY1112334T1 (el) 2015-12-09
JP2012115275A (ja) 2012-06-21
ATE537258T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
ES2333772T3 (es) Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas.
ES2292242T5 (es) Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
ES2577532T3 (es) Nueva composición y métodos para el tratamiento de enfermedades relacionadas con el sistema inmune
US20080160021A1 (en) Il-17 homologous polypeptides and therapeutic uses thereof
US7473763B2 (en) Receptor for IL-17 homologous polypeptides and uses thereof
ES2291198T3 (es) Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico.
JP2009189367A (ja) Ｉｌ−１７相同的ポリペプチドとその治療上の用途
ES2295224T3 (es) Anticuerpo antagonista anti-pro842.
ES2370423T3 (es) Polipéptidos homólogos il-17 y sus utilizaciones terapéuticas.
ES2317847T3 (es) Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico.
JP2016047051A (ja) Ｉｌ−１７相同的ポリペプチドとその治療上の用途
EP1897943A2 (en) IL-17 homologous polypeptides and therapeutic uses thereof